Compare HFWA & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | DRTS |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 978.2M |
| IPO Year | 1997 | N/A |
| Metric | HFWA | DRTS |
|---|---|---|
| Price | $28.85 | $9.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $30.50 | $8.67 |
| AVG Volume (30 Days) | 199.8K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $45.85 | N/A |
| Revenue Next Year | $7.83 | $699.98 |
| P/E Ratio | $59.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.32 | $2.87 |
| 52 Week High | $28.98 | $11.62 |
| Indicator | HFWA | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 65.12 | 52.11 |
| Support Level | $26.36 | $6.59 |
| Resistance Level | $28.98 | $11.48 |
| Average True Range (ATR) | 0.61 | 0.95 |
| MACD | 0.17 | -0.18 |
| Stochastic Oscillator | 91.85 | 39.15 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.